Director, Clinical Pharmacology
Vertex
Kefeng Sun, Ph.D. is currently a Director of Clinical and Quantitative Pharmacology at Vertex. After attaining his doctoral degree in Pharmaceutical Sciences from the University of Michigan College of Pharmacy, he honed his skills in small molecular ADME at Eli Lilly & Company. Dr. Sun joined Shire (now part of Takeda) in late 2017, first as a DMPK and QSP scientist and then a clinical pharmacologist working on Takeda’s investigational small molecular and protein drugs as well as gene therapy programs. In January 2025, Dr. Sun joined Vertex as a Director and Group Lead in Clinical Pharmacology. His main interest is utilizing modeling & simulation, including physiologically based PK/PD, quantitative systems pharmacology and pharmacometrics, to enable translational and clinical approaches from bench to bedside for novel therapeutic modalities.
Cell and Gene Therapy: Transforming Treatment Paradigms for Patient-Centric Care
Friday, April 4, 2025
10:00 AM - 2:00 PM East Coast USA Time